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Abstract
As the scientific community globalizes, it is increasingly important to understand the effects of international collaboration
on the quality and quantity of research produced. While it is generally assumed that international collaboration enhances
the quality of research, this phenomenon is not well examined. Stem cell research is unique in that it is both politically
charged and a research area that often generates international collaborations, making it an ideal case through which to
examine international collaborations. Furthermore, with promising medical applications, the research area is dynamic and
responsive to a globalizing science environment. Thus, studying international collaborations in stem cell research elucidates
the role of existing international networks in promoting quality research, as well as the effects that disparate national
policies might have on research. This study examined the impact of collaboration on publication significance in the United
States and the United Kingdom, world leaders in stem cell research with disparate policies. We reviewed publications by US
and UK authors from 2008, along with their citation rates and the political factors that may have contributed to the number
of international collaborations. The data demonstrated that international collaborations significantly increased an article’s
impact for UK and US investigators. While this applied to UK authors whether they were corresponding or secondary, this
effect was most significant for US authors who were corresponding authors. While the UK exhibited a higher proportion of
international publications than the US, this difference was consistent with overall trends in international scientific
collaboration. The findings suggested that national stem cell policy differences and regulatory mechanisms driving
international stem cell research in the US and UK did not affect the frequency of international collaborations, or even the
countries with which the US and UK most often collaborated. Geographical and traditional collaborative relationships were
the predominate considerations in establishing international collaborations.
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Introduction
The scientific community is increasingly global; new scientific
results are disseminated worldwide within hours of publication.
From 1998 to 2008, the absolute number of internationally co-
authored publications in science (including social sciences) and
engineering almost doubled from 98,424 to 180,783 (representing
over 20% of total publications in 2008) [1]. As the number of
internationally co-authored journal articles proliferates, it is
imperative to understand the impact that cross-border collabora-
tions may have on the quality, productivity, and effectiveness of
the research produced.
Previous research has established that articles with authors from
multiple countries were cited twice as frequently as publications
authored by scientists working at a single institution or within a
single country [2,3]. Moreover, scholarship reveals that multi-
institutional collaboration, particularly collaborations that involve
institutions in different nations, also increased citation rate [2,4,5].
Reviewing overall science and engineering publications in 2008,
43% of internationally co-authored papers included US-based
researchers. Germany and the UK shared the next highest
percentage, with 19% each [1]. While Germany shares the second
highest percentage of stem cell publications, Germany’s stem cell
policy is similar to US policy from 2001 to 2008, with restrictions
on human embryonic stem cell (hESC) research based on the time
the cells were derived [6]. In contrast to the US, the UK has a
more permissive approach within a highly detailed regulatory
system. The UK and US were therefore selected for this study due
to their policy differences and high frequency of collaborations.
Examining the impact of collaboration in these two countries will
highlight the effects of disparate policy regimes on scientific
research.
Due to policy disparities between nations and extant interna-
tional research networks, stem cell research is the ideal research
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cell research—embryonic, cord blood, adult, and induced
pluripotent (iPS)—has the potential to revolutionize medicine
and provide scientists with an improved understanding of cell
development and specialization. Prior studies of stem cell research
in the Middle East suggest that international collaborations
resulted in stem cell publications with a higher citation rate than
articles published by a single nation from the region [7]. However,
no studies of collaborations in stem cell research have been
conducted on publications with co-authors from two of the leading
countries in this field, the US and the UK. Potential stem cell
therapies offer the promise of possible treatments for debilitating
injuries, e.g., spinal cord and brain trauma, and cures for
debilitating diseases and conditions such as Parkinson’s disease,
diabetes, and blindness [8,9]. At the same time, progress on hESC
research in the US, in particular, is limited by policy restrictions
and political uncertainties. For these reasons, stem cell research
presents a unique opportunity not only to study international
collaboration per se, but collaboration under very different policy
regimes.
Research from the US and the UK involving hESCs is
conducted under quite different legislative policies. US policy on
stem cell research has developed sporadically, has historically been
more inhibitive than supportive, and has included only federal
government funding of the research. By contrast, UK policy has
developed in a more permissive, although highly regulated,
manner [10–12].
Since 1978, following the first successful in vitro fertilization
(IVF) birth, the UK has progressively built upon its policy. The
first set of recommendations governing embryo research appeared
in the Warnock Report, which was released in 1984 [13]. This
report encouraged regulated embryo research. It also limited
embryo research to the first 14 days of development, a standard
now applied worldwide. In 1990, legislation to regulate embryo
research, the Human Fertilization and Embryology (HFE) Act,
was passed in the UK. This established the Human Fertilization
and Embryology Authority (HFEA), which monitors and grants
licenses for all embryo research, regardless of the source of funding
[14]. As science progressed, the UK revised the HFE Act in 2001
and 2008 to take into account scientific advances such as the
creation of the first hESC line [15]. In 2003, in order to provide
storage for hESC lines created using HFEA licenses, the UK also
launched the UK Stem Cell Bank. The UK has identified new
funds specifically for stem cell research, apparently with little
controversy [16]. It has also encouraged international collabora-
tions through its commonwealth offices.
In contrast to the UK, the US has been slow to adopt a
comprehensive human embryo policy. In 1978, President Carter
established the Ethics Advisory Board to monitor embryonic
research, but after the election of President Reagan, the board
never met and never approved a single project [10]. The board
was eventually dismantled by the Clinton administration, which
planned to provide funding for human embryo research. However,
while the Clinton policy was being put in place, Congress passed
the Dickey-Wicker amendment. This amendment, which has been
added to the funding bill for the National Institutes of Health
(NIH) each year since 1995, forbids the use of federal funds for
research in which a human embryo is destroyed or subjected to
risk of injury or death [17]. The amendment also bans federal
funding for the creation of hESC cell lines, which were first
derived in 1998, four years after the amendment was enacted.
NIH carefully studied the Dickey-Wicker amendment and
determined that it would permit funding of hESC research on
stem cell lines derived from donated IVF embryos supported by
non-federal funds. However, before any such research could be
funded, Clinton left office. Limited hESC research funded by the
federal government was allowed under President G.W. Bush, but
only for lines created before August 9, 2001 (21 hESC lines) [18].
In 2009, under the Obama administration, federal funding for
stem cell lines created after August 9, 2001, became available to
researchers, but under strict guidelines. It is still not possible to use
federal funds for the derivation of hESC lines regardless of the
method used. In the US, there is no restriction on hESC research
or even reproductive cloning as long as no federal funds are
involved. Any potential stem cell therapy, however, requires
demonstration of safety and efficacy and final approval by the US
Food and Drug Administration (FDA).
The lack of a coherent approach and set of policies for human
embryo and hESC research in the US has resulted in the most
recent policy crisis. On August 23, 2010, US District Judge Royce
Lamberth ruled that the Dickey-Wicker amendment prohibited
federal funding of any hESC for research [19]. This decision
translated into an immediate injunction halting research at the
NIH (both intramural and extramural research) and impacted
grant decisions worth $140 million [20]. Approximately two weeks
later, on September 9, 2010, a federal appeals court lifted the
injunction and agreed to listen to arguments for and against the
ban. The court still has not ruled on the case itself. With policy
implications ranging from a permanent injunction or ban of hESC
research to possible congressional legislation explicitly permitting
federal funding of hESC, the current precarious nature of hESC
research in the United States highlights the difficulties scientists
face and serves as a possible barrier to international collaborations
involving US researchers.
In addition to policy disparities among nations, a second aspect
of stem cell research that makes it an ideal research area for the
study of international collaborations is its intrinsically international
nature. This is evident in the various existing organizations that
facilitate the exchange of research findings and policy information,
e.g., the International Society for Stem Cell Research (www.isscr.
org), the International Stem Cell Forum (www.stem-cell-forum.
net), and the International Consortium of Stem Cell Networks
(www.stemcellconsortium.org). These international organizations
formed while the field was still young. This presents the
opportunity to study a field that is characterized by high levels
of international collaborative research from the start.
The goal of this article is to identify the impact of international
collaboration on citation rates in stem cell research in the US and
the UK. We specifically examined if international collaborations
increase citation rates, and if differing research regulations and
legislations affect the frequency of collaboration. Publications were
examined from the US and the UK for the year 2008. Citation
rates, country attribution, and collaborations were recorded for
each article. In addition, we analyzed the political landscape and
other driving factors, which may have contributed to the number
and impact of these international collaborations. The data
confirmed that, for both the US and the UK, international
collaborations significantly increased an article’s impact (as
measured by citation rates). It also demonstrated that the UK
participated in a higher percentage of international publications
than the US, which is congruent with trends of international
collaborations in all sciences [1]. Four of the top five collaborators
with the US were Germany, UK, Canada, and China, countries
that were consistent across all fields of science, indicating that
traditional collaborative relationships also predominated in
international stem cell collaborations [1]. This suggests that
policies and regulatory differences in the UK and US did not
influence the frequency of international collaborations nor the
Stem Cell Collaborations in the US and UK
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Methods
Article Collection and Sorting
Publications used for this study were extracted from Thomas
Reuters’ Institute of Scientific Information (ISI) Science Citation
Index. Stem cell research articles were identified by entering the
search string: TS=(‘‘stem cell*’’) AND CU=Respective Country
AND Document Type=(Article), and setting the time period to
2008. The UK data was collected by searching for articles from
England, Scotland, Wales, and Northern Ireland. All articles for
both the US and UK were collected on December 8, 2010.
Records were sorted to eliminate articles (UK or US) when the
corresponding author’s address listed did not match the address of
that individual when the research was conducted. Also excluded in
this study were publications not indexed by ISI, non-English
language journals, and articles that did not use stem cells in an
experimental context—such as reviews, book chapters, abstracts,
and conference proceedings. Self-citations were not removed.
Categorical Assignment of Articles
The articles collected were divided into three categories:
independent (Indep), international-corresponding (Intl-C), and
international-secondary (Intl-S). Articles were considered indepen-
dent papers only when researchers from either the US or the UK
were listed. Articles were considered international-corresponding
works when a scientist from the US or the UK was the
corresponding author, and the article listed authors from two or
more countries. The corresponding author was determined from
the reprint address. Articles that listed authors from two or more
countries—one of which was the US or the UK—but did not list a
scientist from one of these countries as the corresponding author
were considered international-secondary papers.
Statistical Analysis
Unpaired, two-tailed, Student’s t-tests assuming equal variance
were conducted with the alpha value set to 0.05.
Results
A literature search of 2008 publications generated 3176 articles
that listed at least one US scientist as an author, and a total of 616
papers that listed at least one UK scientist as an author (Figure 1).
While US researchers published over five times more often than
UK researchers in absolute numbers, the publication rates per
million inhabitants were very similar—10.2 articles per million
individuals for the US and 10.0 articles per million individuals for
the UK [21,22].
The collaboration rates for these publications were subsequently
investigated. Proportionally, the UK engaged in appreciably more
collaborative research in both a corresponding and secondary
capacity—18.8% and 34.4% (total 53.2%), respectively, compared
with 15.5 and 11.5% (total 27.1%) for the US (Figures 2 and 3).
The data is consistent with overall trends in collaborations which
show the US collaboration rates in all sciences (including
engineering and social science research) at 30% and the UK at
49% [1].
The citation rates for these articles broadly ranged from 0 to
196 citations for UK publications and from 0 to 592 citations for
US articles (Table 1). With the exception of a few articles, the
majority of publications from both nations were cited fewer than
10 times. Sixty-one percent of the publications involving the US or
UK received 10 or fewer citations, with 12% of them receiving 0–
1 citations. The distribution of papers based on the citation rate
were similar for the US and UK for rates under 100 citations.
Papers with 100+ citations made up 1.8% (57 papers) of total US
publications while they were only 0.81% (5 papers) of total UK
publications. No UK papers had over 200 citations, but 19 US
papers did.
Overall citations from the US papers were slightly higher than
UK papers, (15.9 versus 13.6), but the results were not statistically
significant. Reviewing data for each country, citation rates for UK
Figure 1. Comparison of US and UK articles. While the United
Kingdom (red) collaborates proportionally more than the United States
(blue), with 53.4% of their publications the result of international
collaborations versus 27.1% in the United States, the United States
produced a higher absolute number of publications (3176 versus 616 in
the United Kingdom).
doi:10.1371/journal.pone.0017684.g001
Figure 2. Collaborative status of US articles. Of the 3176 papers
generated by the US, 15.6% (494) were international-corresponding
(Intl-C), 11.5% (366) were international-secondary (Intl-S), and 72.9%
(2316) were independent papers (Indep).
doi:10.1371/journal.pone.0017684.g002
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an international collaboration rather than independently produced
by the UK. UK-independent articles averaged 10.1 citations while
articles listing a UK scientist as the international-corresponding or
an international-secondary author averaged 13.8 (p=0.01) and
18.4 citations (p,0.01), respectively (Figure 4). The increased
citation rate of articles by US scientists collaborating with
international co-authors was slightly less dramatic, but still
statistically significant (p,0.01 for papers on which the US was
the corresponding author versus US independent papers). US-
independent articles averaged 15.0 citations, and publications
listing a US scientist as the international-corresponding and
international-secondary author averaged 20.3 and 15.3 citations,
respectively. While the citation rate was slightly increased for
international papers on which a US scientist was a secondary
author, this difference was not found to be statistically significant,
indicating that it is not as beneficial for US authors to be
secondary contributors. These figures suggest that scientists in
both the UK and US produce higher-impact stem cell research
when collaborating with foreign counterparts. But US scientists
find a more dramatic increase in citation rates when they are
corresponding authors and the UK scientists had the highest rate
for articles as secondary authors.
The publications on which US and UK researchers had
international co-authors were then analyzed to determine the
countries with which the US and UK scientists most often
collaborated (Table 2 and 3). The United States had 52
collaborating countries with the top ten collaborators representing
60.0% of the international publications. The citation average of
the top ten collaborators ranged from 9.99 (China) to 26.4 (Spain).
In contrast, the UK had 42 collaborating countries. The top 10
represented 52.4% of the international publications, and the
citation average of the top ten collaborators ranged from 15.0
(Switzerland) to 40.3 (Canada). All of the top collaborators (except
for China and South Korea) resulted in average citations which
were higher than the citations of papers with US- or UK-only
authorships.
Discussion
As scientific research becomes increasingly global, it is
important to understand how increased international collaboration
affects the impact of the research produced. Stem cell research is
an ideal area for the study of scientific globalization. It is heavily
influenced by policy decisions, which differ markedly across
borders, and is the subject of many international dialogues and
networks. US and UK articles were chosen for this study because
these two countries have disparate policy environments, yet are
both leaders in stem cell research.
Here, we used citation rates as a measure of impact to evaluate
the significance of publications. Citation rates are one quantitative
measure of publication quality that is used across disciplines and
across national contexts. We recognize this is not the only way, or
even the best way, to measure quality, but that it is the simplest,
taking into account the scale of research in the US and UK. This
study demonstrated that UK stem cell researchers engaged in
international collaborations proportionally more frequently than
US investigators. We have also shown that stem cell articles
resulting from UK and US international collaborations were cited
significantly more often than those generated by solely UK or US
investigators. This increase was not as large for the US as it was for
the UK, yet both countries benefited from international
collaborations.
There are many possible reasons why collaborative publications
garner higher average rates of citation than single author,
institution, or country publications. Collaboration can be benefi-
cial through the sharing of resources, ideas, expertise, and
institutions. Collaborations, especially international collaborations,
might also provide a researcher, and consequently his or her work,
more exposure within the field. Collaborating with a well-
established laboratory may provide a mechanism for newer and
less well-known researchers to network within the stem cell
research community. It has been proposed that the number of
authors on a paper increases the citation rate simply due to
increased self-citation; however, studies have indicated that this
does not apply to all fields and, thus far, the phenomenon has not
been examined in international collaborations [4,23–26].
By examining citation rates in international collaborations, the
present study is a first step in understanding the possible benefits of
international collaboration. Some fields are more likely to
encourage and engage in international collaboration. Similarly,
Figure 3. Collaborative status of UK articles. Of the 616 articles
pulled for the UK, 18.8% (116) were international-corresponding (Intl-C),
34.4% (212) were international-secondary (Intl-S), 46.8% (288) were
independent (Indep).
doi:10.1371/journal.pone.0017684.g003
Table 1. Distribution of articles by citation rate and
percentage of total for US and UK.
# of Citations US % of Total US UK % of Total UK
0 176 5.54 34 5.52
1–5 1007 31.7 200 32.5
6–10 745 23.5 140 22.7
11–50 1082 34.1 220 35.7
51–100 109 3.43 17 2.76
101–200 38 1.20 5 0.81
201–500 18 0.57 0 0
501+ 1 0.03 0 0
doi:10.1371/journal.pone.0017684.t001
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international collaborations; these individuals may be well
established in their respective field and have both the funding
and institutional support to pursue collaborative initiatives. With
so many variables, it is difficult to identify with any certainty the
aspects of collaborations, particularly international collaborations,
which result in higher citation rates. The goal of the paper,
however, was not to provide an explanation of how collaborations
increase citation rates. Instead, we sought to determine if this trend
has persisted in biomedical research, specifically stem cell research,
in two nations with mature science and technology research and
development programs, and how policy differences affected the
nature of stem cell collaboration.
The data demonstrated that it was beneficial for UK researchers
to participate in these collaborations, as the number of citations
increased significantly when a UK researcher was the correspond-
ing author or a secondary author. While it was beneficial for US-
based researchers to engage in international collaborations, it
appeared that the benefit was most salient when the US researcher
took the role of corresponding author. The higher citation rates of
papers by US researchers in the position of corresponding authors
may be the result of the large biomedical research infrastructure
and numerous funding opportunities that exist in the US.
There are many possible factors that account for the increased
participation by UK investigators in international collaborations
relative to the US. The UK has a multitude of countries in its
immediate proximity with which to collaborate, many of which
boast well-developed biomedical research facilities. Although the
US is geographically larger than the UK, the pool of neighboring
countries with which its investigators can easily collaborate is far
more limited.
Additionally, the UK has fewer scientists per capita than the
US; 0.04% of UK inhabitants hold scientific degrees as opposed to
0.07% of the US population (2,301,000 UK scientists versus
22,630,000 US scientists) [21,22,27,28]. This population differ-
ence could lead to a lower rate of domestic co-authorships in the
UK, as UK researchers do not have as many options as US
researchers when selecting a domestic partner for collaboration
[3]. While previous research concluded that international
collaborations could more often be traced to historical and
linguistic factors than the number of scientists in a country, the
population difference can nevertheless serve as one factor
encouraging increased international collaborations [2].
Figure 4. Average number of citations for US and UK paper. US publications (blue) UK publications (red) were evaluated in four categories:
overall citation rate (All); independent (Indep); international-corresponding (Intl-C); and international-secondary (Intl-S). Significant differences
statistically were seen between: (A) US Indep vs. Intl-C, p,0.01; (b) US Intl-C vs Intl-S, p=0.04; (C) UK Indep vs.Intl-C, p=0.01; (D) UK Indep vs. Intl-S,
p,0.01; and (E) US Indep vs. UK Indep, p,0.01.
doi:10.1371/journal.pone.0017684.g004
Table 2. Top 10 countries with collaborated with the United
States.
Country
Average
Citations
Total # of
Publications % Total
Germany 22.89 138 16.0
Japan 23.17 113 13.1
UK 21.07 105 12.2
Canada 18.40 101 11.7
China 9.99 100 11.6
Italy 17.76 71 8.26
France 17.50 48 5.58
South Korea 10.77 47 5.47
Netherlands 22.32 41 4.77
Spain 26.41 39 4.53
Remaining 42 Countries 11.90 344 40.0
doi:10.1371/journal.pone.0017684.t002
Table 3. Top 10 countries with collaborated with the United
Kingdom.
Country
Average
Citations
Total # of
Publications % Total
USA 21.23 128 39.0
Germany 22.24 70 21.3
Italy 18.62 39 11.9
Netherlands 17.50 40 12.2
France 23.45 33 10.1
Switzerland 14.96 28 8.54
Sweden 21.72 25 7.62
Spain 27.35 23 7.01
Canada 40.32 22 6.71
Japan 22.30 20 6.10
Remaining 32 Countries 17.56 156 47.6
doi:10.1371/journal.pone.0017684.t003
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be that funding levels for stem cell research are lower in the UK.
In 2007, the NIH invested $968 million in stem cell research in the
US, approximately $3.12 per individual (total US population)
[20,26]. In contrast, the two UK research councils that fund stem
cell research, the Medical Research Council (MRC) and the
Biotechnology and Biological Sciences Research Council
(BBSRC), spent £33.9million ($69.5 million), or approximately
$1.21 per UK resident [22,29]. The United Kingdom’s overall
funding for stem cell research in 2007, including federal and
private funding, was £62 million ($122.5 million), or approx-
imately $2.05 per individual [22,29]. This was substantially less
than the US’s NIH funding, and it is likely that support from the
European Union (EU) compensates for part of the difference.
The EU, in which the UK is a member, heavily promotes
collaborative research and could be another contributing factor to
the proportionally higher rate of UK investigators’ international
collaboration. In 2000, the EU took steps to unify research efforts
with the creation of the European Research Area [30]. While stem
cell research, particularly hESC research, is a controversial topic
in Europe, the EU has funded and continues to fund stem cell
research. Under the Sixth Framework Program (2002–2006), the
EU specifically targeted collaborative research projects in stem cell
research and despite considerable controversy, has committed to
include stem cell research as a part of its J54 billion
(approximately $69 billion) research budget for the Seventh
Program Framework (FP7), in effect from 2007 to 2013 [31]. As
collaboration and networking in biomedical research are increas-
ingly important, the bulk of the FP7 will go toward collaborative
research in the EU and beyond through a variety of funding
schemes, including collaborative projects (between member states),
coordination/support actions, and joint technology initiatives
[32,33].
The US and UK shared seven of the same top 10 collaborators
(although in a different order): Germany, Italy, Netherlands,
France, Spain, Canada, and Japan (see Tables 2 and 3). While the
US was the top collaborator for the UK, the UK ranked third on
the list for the US. The countries that did not overlap were China
and South Korea (top collaborators with the US) and Switzerland
and Sweden (top collaborators with the UK). The US results were
consistent with previous studies of co-authorship by the National
Science Foundation, which included all publications from natural
science, social science, and engineering research in 2008. That
report determined that US authors were most likely to collaborate
with the UK (13.9%), Germany (12.7%), Canada (12.0%), and
China (10.4%) [1].
Japan and Germany were two major collaborators with both the
US and UK. While progress on hESC in Japan has proceeded
slowly due to the need to establish a regulatory framework, Japan’s
stem cell research policies are largely permissive. As a result, large
investments have been made in centers such as the RIKEN Center
for Developmental Biology (www.cdb.riken.jo.jp) and the Institute
for Frontier Medical Sciences at Kyoto University (www.frontier.
kyoto-u.ac.jp) [34]. With a 2004 legislation change that permitted
the creation of human embryos for stem cell research and the
development of induced pluripotent stem (iPS) cells by Shinya
Yamanaka’s team at the Kyoto University Institute for Frontier
Medical Sciences, the climate of stem cell research in Japan has
become very advanced, thus attracting many international
collaborators [35].
Germany, unlike Japan, has a fairly restrictive stem cell research
policy, and bans the production of hESC lines. The loophole to
this policy is that hESCs may be imported; this was directly
addressed in Germany’s 2002 Stem Cell Act, which permitted the
use of stem cells created before January 1, 2002 for high-ranking
research objectives [36]. Despite these restrictions, the German
Federal Ministry of Education and Research (BMBF) as well as the
German Science Foundation (DFG) have invested heavily,
approximately J230 million ($300 million) since 1990 in
regenerative medicine [36]. Germany is also currently one of the
only six countries collaborating with the California Institute for
Regenerative Medicine (CIRM), with the UK, Canada, Australia,
Spain, and Japan being the others [37]. In addition to these efforts,
various German grant organizations such as the Alexander von
Humboldt Foundation and the DFG have targeted international
research cooperation, thus helping to account for Germany’s high
rate of collaboration with the UK and the US [38]. This is also
consistent with Germany being the top international collaborator
with the US for 2008 in all fields of science and engineering
research [1].
Of the top nations collaborating with the US or UK, the only
non-overlapping countries were China and South Korea (both US
collaborations) and Switzerland and Sweden (both UK collabo-
rators). Asian collaborations are common for US researchers for
all sciences according to the National Science and Engineering
Indicators [1]. China does not object to the use of hESCs and
permits the production of new hESC lines as well as therapeutic
cloning [39]. South Korea also places a high priority on stem cell
research and allows therapeutic cloning [40]. Furthermore, many
Asian students study abroad in the US, which could lead to
collaborations if they return home [41]. But unlike the other
countries in the top ten for the US, Chinese and South Korean
collaborations resulted in average citations (9.99 for China and
10.77 for South Korea) which were lower than the average of US-
only publications (15.01).
Investigators in the UK, on the other hand, likely collaborated
more often with Switzerland and Sweden because of their
proximity, their membership in the Council of Europe, and their
permissive approach toward stem cell research. Both Switzerland
and Sweden allow for the derivation of human embryonic stem
cell lines, and Sweden also allows therapeutic cloning [8,42]. In
2004, a national referendum was put forth in Switzerland, with
two-thirds of the voters deciding to support embryonic stem cell
research [43]. Sweden also has a well-established biomedical
industry with public and political support for stem cell research.
Lines created from discarded embryos as well as through somatic
cell nuclear transfer are permitted [44]. Two of the human
embryonic stem cell lines approved by the National Institutes of
Health for use in US federal government funded research are from
the company Cellartis AB in Sweden [45].
This study is an initial investigation of the impact of
international collaboration on publications in stem cell research.
The results indicated that international collaborations, on average,
significantly increased article citation rates (our metric for impact)
for the UK and US investigators. Additional research is necessary
to address the mechanisms of a successful collaboration by
examining the extant research networks and elucidating best
practice methodology to improve these interactions. Although
citation rate was taken as an appropriate measure of publication
quality for this study, additional indicators of quality and
significance—such as scientific honors and awards, research
funding, patents and infrastructure—should also be considered
in determining the impact of international collaboration. As
research globalizes and national funding agencies reward collab-
orative efforts, understanding the characteristics of a successful
collaboration is crucial to maximizing the resources available for
stem cell research and advancing this scientific field.
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